Regulatory effects of interferon-β on osteopontin and interleukin-17 expression in multiple sclerosis

Journal of Interferon and Cytokine Research

Volumn 30, Issue 10, 2010, Pages 751-757

  Hong, Jian ^a   Hutton, George J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 22; ORPHAN NUCLEAR RECEPTOR; OSTEOPONTIN;

ANTIGEN PRESENTATION; APOPTOSIS; CELL DIFFERENTIATION; CELL LINEAGE; CELL MIGRATION; CELL SURVIVAL; DOWN REGULATION; DRUG MECHANISM; ENCEPHALOMYELITIS; ENZYME INDUCTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; MACROPHAGE; MULTIPLE SCLEROSIS; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL; THERAPY EFFECT; TREATMENT RESPONSE;

DOWN-REGULATION; HUMANS; INTERFERON-BETA; INTERLEUKIN-17; MULTIPLE SCLEROSIS; OSTEOPONTIN;

EID: 77957352556     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2010.0082     Document Type: Review

References (58)

1. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico M.E., Jansson M., Zawaideh S, Rittling SR, Denhardt D.T., Glimcher MJ, Cantor H. 2000. Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity. Science '287(5454):860-864.
2. Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, Naves R, Han M, Zhong F, Castellanos JG, Mair R, Christakos A, Kolkowitz I, Katz L, Killestein J, Polman CH, de Waal Malefyt R, Steinman L, Raman C. 2010. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med '16(4):406-412.
3. Barna BP, Chou SM, Jacobs B, Yen-Lieberman B, Ransohoff RM 1989. Interferon-beta impairs induction of HLA-DR antigen expression in cultured adult human astrocytes. J Neuroimmunol '23(1):45-53.
4. Boniface K, Blom B, Liu Y.J., de Waal Malefyt R. 2008. From interleukin-23 to T-helper 17 cells: Human T-helper cell differentiation revisited. Immunol Rev '226:132-146.
5. Boz C, Ozmenoglu M, Velioglu S., Kilinc K, Orem A, Alioglu Z., Altunayoglu V. 2006. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. Clin Neurol Neurosurg '108(2):124-128.
6. Burdo TH, Wood MR, Fox HS 2007. Osteopontin prevents monocyte recirculation and apoptosis. J Leukoc Biol '81(6): 1504-1511.
7. Cao Z, Dai J, Fan K., Wang H, Ji G, Li B., Zhang D, Hou S, Qian W, Zhao J, Guo Y. 2008. A novel functional motif of osteopontin for human lymphocyte migration and survival. Mol Immunol '45(14):3683-92.
8. Chabas D, Baranzini SE, Mitchell D, Bernard C.C., Rittling SR, Denhardt DT, Sobel RA, Lock C, Karpuj M., Pedotti R, Heller R, Oksenberg JR, Steinman L. 2001. The influence of the proinflammatory cytokine, osteopontin, on autoimmune de-myelinating disease. Science '294(5547):1731-1735.
9. Chen M, Chen G, Nie H., Zhang X, Niu X, Zang Y.C., Skinner SM, Zhang JZ, Killian JM, Hong J. 2009a. Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS. Eur J Immunol '39(9):2525-2536.
10. Chen YJ, Wei YY, Chen H.T., Fong YC, Hsu CJ, Tsai CH, Hsu H.C., Liu SH, Tang CH. 2009b. Osteopontin increases migration and MMP-9 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chon-drosarcoma cells. J Cell Physiol '221(1):98-108.
11. Comabella M, Pericot I, Goertsches R., Nos C, Castillo M, Blas Navarro J, Rio J, Montalban X. 2005. Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol '158(1-2):231-239.
12. Cua DJ, Sherlock J, Chen Y., Murphy CA, Joyce B, Seymour B, Lucian L., To W, Kwan S, Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D. Kastelein RA, Sedgwick JD. 2003. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature '421(6924):744-748.
13. de Andres C., Aristimuno C, de Las Heras V, Martinez-Gines ML, Bartolome M, Arroyo R, Navarro J, Gimenez-Roldan S, Fernandez-Cruz E, Sanchez-Ramon S. 2007. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: An ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis. J Neuroimmunol 182(1-2): 204-211.
14. Diveu C, McGeachy MJ, Boniface K, Stumhofer J.S., Sathe M., Joyce-Shaikh B, Chen Y, Tato C.M., McClanahan TK, de Waal Malefyt R, Hunter CA, Cua DJ, Kastelein RA. 2009. IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J Immunol '182(9):5748-5756.
15. Fan K, Dai J, Wang H., Wei H, Cao Z, Hou S., Qian W, Li B, Zhao J, Xu H, Yang C, Guo Y. 2008. Treatment of collagen-induced arthritis with an anti-osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells. Arthritis Rheum '58(7):2041-2052.
16. Galicia G, Kasran A, Uyttenhove C., De Swert K, Van Snick J, Ceuppens JL. 2009. ICOS deficiency results in exacerbated IL-17 mediated experimental autoimmune encephalomyelitis. J Clin Immunol '29(4):426-433.
17. Gravallese EM. 2003. Osteopontin: A bridge between bone and the immune system. J Clin Invest '112(2):147-149.
18. Guo B, Chang EY, Cheng G. 2008. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest '118(5):1680-1690.
19. Haak S, Croxford AL, Kreymborg K, Heppner F.L., Pouly S., Becher B, Waisman A. 2009. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J Clin Invest '119(1):61-69.
20. Hall GL, Wing MG, Compston D.A., Scolding NJ 1997. beta-Interferon regulates the immunomodulatory activity of neonatal rodent microglia. J Neuroimmunol '72(1):11-19.
21. Higuchi Y, Tamura Y, Uchida T., Matsuura K, Hijiya N, Yamamoto S. 2004. The roles of soluble osteopontin using osteopontin-transgenic mice in vivo: Proliferation of CD4+ T lymphocytes and the enhancement of cell-mediated immune responses. Pathobiology '71(1):1-11.
22. Hofstetter HH, Ibrahim SM, Koczan D, Kruse N., Weishaupt A, Toyka KV, Gold R. 2005. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalo-myelitis. Cell Immunol '237(2):123-130.
23. Hur EM, Youssef S, Haws M.E., Zhang SY, Sobel RA, Steinman L. 2007. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol '8(1):74-83.
24. Jansson M, Panoutsakopoulou V, Baker J., Klein L, Cantor H. 2002. Cutting edge: Attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. J Immunol '168(5):2096-2099.
25. Jiang H, Milo R, Swoveland P., Johnson KP, Panitch H, Dhib-Jalbut S. 1995. Interferon beta-1b reduces interferon gamma-induced antigen-presenting capacity of human glial and B cells. J Neuroimmunol '61(1):17-25.
26. Komiyama Y, Nakae S, Matsuki T., Nambu A, Ishigame H, Kakuta S., Sudo K, Iwakura Y. 2006. IL-17 plays an important role in the development of experimental autoimmune encephalo-myelitis. J Immunol '177(1):566-573.
27. Korporal M, Haas J, Balint B., Fritzsching B, Schwarz A, Moeller S., Fritz B, Suri-Payer E, Wildemann B. 2008. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells. Arch Neurol '65(11):1434-1439.
28. Kozovska ME, Hong J, Zang Y.C., Li S., Rivera VM, Killian JM, Zhang JZ 1999. Interferon beta induces T-helper 2 immune deviation in MS. Neurology 53(8):1692-1697.
29. Langer JA. 2007. Interferon at 50: New molecules, new potential, new (and old) questions. Sci STKE 2007(405):pe53.
30. Lee WW, Kang SW, Choi J, Lee S.H., Shah K., Eynon EE, Flavell RA, Kang I. 2010. Regulating human Th17 cells via differential expression of IL-1 receptor. Blood '115(3):530-540.
31. Leppert D, Waubant E, Burk M.R., Oksenberg JR, Hauser SL 1996. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol '40(6):846-852.
32. Liu X, Leung S, Wang C., Tan Z, Wang J, Guo T.B., Fang L., Zhao Y, Wan B, Qin X, Lu L, Li R, Pan H, Song M, Liu A, Hong J, Lu H, Zhang JZ. 2010. Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease. Nat Med '16(2):191-197.
33. Lou J, Gasche Y, Zheng L., Giroud C, Morel P, Clements J., Ythier A, Grau GE. 1999. Interferon-beta inhibits activated leukocyte migration through human brain microvascular endothelial cell monolayer. Lab Invest '79(8):1015-1025.
34. Ma HL, Liang S, Li J., Napierata L, Brown T, Benoit S., Senices M, Gill D, Dunussi-Joannopoulos K, Collins M, Nickerson-Nutter C, Fouser LA, Young DA. 2008. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest '118(2):597-607.
35. Malik O, Compston DA, Scolding NJ 1998. Interferon-beta inhibits mitogen induced astrocyte proliferation in vitro. J Neuroimmunol '86(2):155-162.
36. Martin-Saavedra F.M., Gonzalez-Garcia C, Bravo B., Ballester S. 2008. Beta interferon restricts the inflammatory potential of CD4(+) cells through the boost of the Th2 phenotype, the inhibition of Th17 response and the prevalence of naturally occurring T regulatory cells. Mol Immunol '45(15):4008-4019.
37. McLaurin J, Antel JP, Yong VW 1995. Immune and non-immune actions of interferon-beta-Ib on primary human neural cells. Mult Scler '1(1):10-19.
38. McRae BL, Picker LJ, van Seventer GA. 1997. Human recombinant interferon-beta influences T helper subset differentiation by regulating cytokine secretion pattern and expression of homing receptors. Eur J Immunol '27(10):2650-2656.
39. Murugaiyan G, Mittal A, Weiner HL 2008. Increased osteo-pontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol '181(11):7480-7488.
40. Namdar A, Nikbin B, Ghabaee M., Bayati A, Izad M. 2010. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): A preliminary study. J Neuroimmunol '218(1-2):120-124.
41. Noronha A, Toscas A, Jensen MA 1993. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol '46(1-2):145-153.
42. Prinz M, Schmidt H, Mildner A., Knobeloch KP, Hanisch UK, Raasch J, Merkler D., Detje C, Gutcher I, Mages J, Lang R, Martin R, Gold R, Becher B, Bruck W, Kalinke U. 2008. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity '28(5):675-686.
43. Rep MH, Hintzen RQ, Polman C.H., van Lier RA. 1996. Re-combinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J Neuroimmunol '67(2):111-118.
44. Rudick RA, Ransohoff RM, Peppler R, VanderBrug Medendorp S, Lehmann P, Alam J. 1996. Interferon beta induces interleukin-10 expression: Relevance to multiple sclerosis. Ann Neurol '40(4):618-627.
45. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L., Fidelus-Gort R, Kasper LH 2008. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: A phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol '7(9):796-804.
46. Shinohara ML, Kim JH, Garcia V.A., Cantor H. 2008. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: Role of intracellular osteopontin. Immunity '29(1):68-78.
47. Steinman L. 2001. Multiple sclerosis: A two-stage disease. Nat Immunol '2(9):762-4.
48. Stromnes IM, Goverman JM 2007. Osteopontin-induced survival of T cells. Nat Immunol '8(1):19-20.
49. Stuve O, Chabot S, Jung S.S., Williams G., Yong VW 1997. Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9. J Neuroimmunol 80(1-2):38-46.
50. Stuve O, Dooley NP, Uhm J.H., Antel JP, Francis GS, Williams G, Yong VW 1996. Interferon beta-1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase-9. Ann Neurol 40(6):853-863.
51. Sugimoto K, Ogawa A, Mizoguchi E., Shimomura Y, Andoh A, Bhan A.K., Blumberg RS, Xavier RJ, Mizoguchi A. 2008. IL-22 ameliorates intestinal inflammation in a mouse model of ul-cerative colitis. J Clin Invest '118(2):534-544.
52. Tzartos JS, Friese MA, Craner M.J., Palace J., Newcombe J, Esiri MM, Fugger L. 2008. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol '172(1):146-155.
53. Vogt MH, Lopatinskaya L, Smits M., Polman CH, Nagelkerken L. 2003. Elevated osteopontin levels in active relapsing-remitting multiple sclerosis. Ann Neurol '53(6):819-822.
54. Weber GF, Cantor H. 1996. The immunology of Eta-1/osteo-pontin. Cytokine Growth Factor Rev '7(3):241-248.
55. Wolk K, Witte E, Wallace E., Docke WD, Kunz S, Asadullah K, Volk H.D., Sterry W., Sabat R. 2006. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: A potential role in psoriasis. Eur J Immunol '36(5):1309-1323.
56. Yushchenko M, Mader M, Elitok E., Bitsch A, Dressel A, Tumani H., Bogumil T, Kitze B, Poser S, Weber F. 2003. Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis. J Neurol '250(10):1224-1228.
57. Zhang X, Jin J, Tang Y., Speer D, Sujkowska D, Markovic-Plese S. 2009. IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation. J Immunol '182(6):3928-3936.
58. Zuvich RL, McCauley JL, Oksenberg J.R., Sawcer SJ, De Jager PL, Aubin C, Cross AH, Piccio L, Aggarwal NT, Evans D. Hafler DA, Compston A, Hauser SL, Pericak-Vance MA, Haines JL. 2010. Genetic variation in the IL7RA/IL7 pathway increases multiple sclerosis susceptibility. Hum Genet '127(5):525-535.